The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence

The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence

The global population is currently experiencing the impact of the SARS-CoV-2 coronavirus, which has caused the Coronavirus Disease 2019 (COVID-19) pandemic. With our profound comprehension of COVID-19, encompassing the involvement sequence of the respiratory tract, gastrointestinal system, and cardi...

Full description

Bibliographic Details
Main Authors:	Mykhailo Buchynskyi, Iryna Kamyshna, Valentyn Oksenych, Nataliia Zavidniuk, Aleksandr Kamyshnyi
Format:	Article
Language:	English
Published:	MDPI AG 2023-04-01
Series:	Viruses
Subjects:	fatty liver disease MAFLD coronavirus disease 2019 SARS-CoV-2
Online Access:	https://www.mdpi.com/1999-4915/15/5/1072

Similar Items

Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study
by: Mykhailo Buchynskyi, et al.
Published: (2024-01-01)

Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis
by: Mykhailo Buchynskyi, et al.
Published: (2023-08-01)

Autophagy Dysregulation in Metabolic Associated Fatty Liver Disease: A New Therapeutic Target
by: Chun-Liang Chen, et al.
Published: (2022-09-01)

What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease
by: Giovanni Targher
Published: (2020-10-01)

Unveiling the potential pleiotropic effects of metformin in treating COVID-19: a comprehensive review
by: Pavlo Petakh, et al.
Published: (2023-10-01)

Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease
by: Chi-Ho Lee, et al.
Published: (2023-01-01)

The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer
by: Suosu Wei, et al.
Published: (2023-02-01)

Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
by: Laura Valenzuela-Vallejo, et al.
Published: (2023-05-01)

Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population
by: Jiahua Fan, et al.
Published: (2021-09-01)

Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management
by: Yanlan Xu, et al.
Published: (2021-10-01)

Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
by: Khamis Al Hashmi, et al.
Published: (2024-03-01)

The F/B ratio as a biomarker for inflammation in COVID-19 and T2D: Impact of metformin
by: Pavlo Petakh, et al.
Published: (2023-07-01)

Nonalcoholic fatty liver disease (NAFLD) among older adults
by: Panyavee Pitisuttithum, et al.
Published: (2022-12-01)

Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis
by: Mykhailo Buchynskyi, et al.
Published: (2023-01-01)

Editorial: The broader aspects of non-alcoholic fatty liver disease in children
by: Claudia Mandato, et al.
Published: (2022-10-01)

Updated upper limits of normal serum alanine aminotrasferase levels for screening metabolic dysfunction-associated fatty liver disease in obese children
by: Yu-Cheng Lin, et al.
Published: (2022-12-01)

Long-Term Adverse Effect of Liver Stiffness on Glycaemic Control in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study
by: Alessandro Mantovani, et al.
Published: (2022-10-01)

Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
by: Xiao-Dong Zhou, et al.
Published: (2022-12-01)

The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
by: Reem Abou Assi, et al.
Published: (2021-03-01)

Association of circulating omentin level and metabolic-associated fatty liver disease: a systematic review and meta-analysis
by: Qin Zhang, et al.
Published: (2023-04-01)

Plasma Calprotectin Levels Associate with Suspected Metabolic-Associated Fatty Liver Disease and All-Cause Mortality in the General Population
by: Arno R. Bourgonje, et al.
Published: (2022-12-01)

Lead exposure as a causative factor for metabolic associated fatty liver disease (MAFLD) and a lead exposure related nomogram for MAFLD prevalence
by: Chenyu Yang, et al.
Published: (2022-10-01)

Pro-Neurotensin as a Potential Novel Diagnostic Biomarker for Detection of Nonalcoholic Fatty Liver Disease
by: Mohamed AA, et al.
Published: (2022-06-01)

Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions
by: Ayokanmi Ore, et al.
Published: (2021-08-01)

From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
by: Marta Flisiak-Jackiewicz, et al.
Published: (2021-03-01)

Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease
by: Tingfeng Wu, et al.
Published: (2021-11-01)

Associations between Adipokines and Metabolic Dysfunction-Associated Fatty Liver Disease Using Three Different Diagnostic Criteria
by: Jie Pan, et al.
Published: (2023-03-01)

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
by: Abdulrahman Ismaiel, et al.
Published: (2022-08-01)

Dietary Patterns Influence Target Gene Expression through Emerging Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease
by: Mohamed Zaiou, et al.
Published: (2021-09-01)

Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – Reconciling the present with the pastKey points
by: Oyekoya T. Ayonrinde
Published: (2021-06-01)

Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
by: Júlia Pauli De Cól, et al.
Published: (2024-03-01)

Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease
by: Hong Fan, et al.
Published: (2023-01-01)

Nonalcoholic Fatty Liver Disease—A Concise Review of Noninvasive Tests and Biomarkers
by: Tamara Bassal, et al.
Published: (2022-11-01)

Adding to the confusion in more than just the name
by: Jacob George
Published: (2023-10-01)

Circadian Misalignment Rather Than Sleep Duration is Associated with MAFLD: A Population-Based Propensity Score-Matched Study
by: Weng Z, et al.
Published: (2021-01-01)

Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study
by: Sara Volpe, et al.
Published: (2022-11-01)

The Triangle of Nonalcoholic Fatty Liver Disease, Metabolic Dysfunction, and Periodontitis: Analysis of the Dental, Oral, Medical and Epidemiological (DOME) Records-Based Nationwide Research
by: Doron Ram, et al.
Published: (2022-12-01)

Garlic (Allium sativum) polysaccharides ameliorates hepatic injury and fat accumulation in mice with metabolic associated fatty liver disease (MAFLD)
by: Jie Liu, et al.
Published: (2022-12-01)

Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
by: Kamlesh K. Bhopale, et al.
Published: (2023-10-01)

Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis
by: Nan Yao, et al.
Published: (2022-06-01)